NeuroBo Pharmaceuticals, Inc. (NRBO)

NeuroBo Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-25.9	-12.47	-13.97	-15.28	-29.68	-21.31
Depreciation & Amortization	0.02	0.01	0.02	0.05	0.05	0.02
Other Amortization	-	-	2.19	-	-	-
Loss (Gain) From Sale of Assets	-	-	0.08	-	-	-
Asset Writedown & Restructuring Costs	-	-	8.21	-	17.34	12.15
Stock-Based Compensation	0.51	0.22	0.85	0.66	0.7	0.12
Other Operating Activities	0.24	-2.95	-7.93	0.02	0.02	1.24
Change in Accounts Payable	1.25	0.11	-0.2	-1.16	1.12	-1.05
Change in Other Net Operating Assets	3.99	4.28	-0.97	0.58	-0.31	1.79
Operating Cash Flow	-19.9	-10.8	-11.71	-15.13	-10.76	-7.04
Capital Expenditures	-0.05	-0.05	-	-0	-0	-0.21
Sale of Property, Plant & Equipment	-	-	0.01	-	-	-
Cash Acquisitions	-	-	-	-0.58	0.07	-5.84
Investing Cash Flow	-0.05	-0.05	0.01	-0.59	0.07	-6.06
Issuance of Common Stock	20	-	32.25	24.12	7.55	0
Other Financing Activities	-0.8	-0.08	-3.57	-2.09	-0.7	-0.07
Financing Cash Flow	19.2	-0.08	28.68	22.03	6.86	24.17
Foreign Exchange Rate Adjustments	-	-	-	-0.01	0	0.01
Net Cash Flow	-0.75	-10.93	16.98	6.3	-3.83	11.08
Free Cash Flow	-19.95	-10.85	-11.71	-15.14	-10.77	-7.25
Free Cash Flow Per Share	-3.86	-2.14	-36.41	-156.98	-159.36	-333.21
Cash Interest Paid	-	-	-	-	-	0
Levered Free Cash Flow	-10.44	-15.55	4.24	-10	-5.77	-2.58
Unlevered Free Cash Flow	-10.44	-15.55	5.61	-10	-5.77	-2.5
Change in Net Working Capital	-5.67	5.8	-9.68	1.14	-1.23	-2.59

Source: S&P Capital IQ. Standard template. Financial Sources.